NantOmics
NantOmics is a privately held molecular diagnostics company within the NantWorks ecosystem that operates CLIA-certified, CAP-accredited laboratories providing integrated panomic profiling—whole genome sequencing, RNA sequencing, and quantitative proteomics—for oncology providers and cancer patients to guide personalized treatment.
- Company typePrivate
- Founded2012
- HeadquartersCulver City, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What NantOmics does
NantOmics, LLC is a privately held molecular diagnostics company headquartered in Culver City, California, and a member of the NantWorks ecosystem of healthcare companies founded by Dr. Patrick Soon-Shiong. The company operates CLIA-certified, CAP-accredited laboratories, including a proteomics-focused facility in Rockville, Maryland acquired through the 2015 purchase of OncoPlex Diagnostics. NantOmics serves oncology healthcare providers and cancer patients with comprehensive molecular profiling designed to inform personalized treatment decisions, primarily in the United States.
The company's core product is the GPS Cancer platform, which employs an integrated panomic approach combining whole genome sequencing of matched tumor and normal samples, RNA sequencing, and mass spectrometry-based quantitative proteomics to identify tumor-specific molecular alterations and disrupted pathways, then matches those alterations to targeted drugs through a proprietary knowledge database of hundreds of oncogenes and thousands of cellular pathways. A complementary offering, Targeted Proteomics, provides mass spectrometry-based protein quantification from FFPE tissue. NantOmics has also developed proprietary machine vision AI software, validated in peer-reviewed studies (Breast Cancer Research, 2020), that classifies aggressive breast cancer subtypes and identifies tumor-infiltrating lymphocytes in lung cancer from whole slide pathology images.
NantOmics generates revenue through laboratory-developed molecular diagnostic testing services and clinical decision-support reports billed to healthcare providers and payors, with distribution leveraged through its strategic partnership with publicly listed NantHealth (NASDAQ: NH) on the GPS Cancer and Liquid GPS platforms. Its go-to-market relies on scientific publications, conference presence at ASCO, AACR, and SABCS, and integration within the broader NantWorks ecosystem, which includes NantKwest, NantCell, NantPharma, NantCapital, and NantCloud. The company has completed two acquisitions (OncoPlex Diagnostics in 2015 and Genos in 2017) and received $250.8 million in funding from NantHealth in 2015 to build out its panomic platform.
NantOmics firmographics
Firmographics- Name
- NantOmics
- Legal name
- NantOmics, LLC
- Website
- https://nantomics.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NantOmics is a privately held molecular diagnostics company within the NantWorks ecosystem that operates CLIA-certified, CAP-accredited laboratories providing integrated panomic profiling—whole genome sequencing, RNA sequencing, and quantitative proteomics—for oncology providers and cancer patients to guide personalized treatment.
- Ownership category
- akta.pro rank
NantOmics industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industries
- Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Reference & Esoteric Testing Laboratories (HLAFAMAJ)
Keywords
Where NantOmics is headquartered
LocationHeadquarters
- HQ city
- Culver City
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
NantOmics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Molecular Diagnostic Testing Services: Laboratory-developed tests providing comprehensive genomic and proteomic analysis for cancer patients, including GPS Cancer and targeted proteomics panels
- Clinical Testing Reports: Actionable intelligence and molecularly-driven decision support reports for cancer patients and their providers at the point of care
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
NantOmics product offering
Product offeringCore offering
NantOmics provides molecular diagnostic testing services that perform whole genome sequencing of matched tumor and normal samples, RNA sequencing, and mass spectrometry-based quantitative proteomics to identify disrupted pathways and match alterations to targeted therapies. The offerings are delivered through CLIA-certified, CAP-accredited laboratories and include the GPS Cancer integrated panomic platform and a Targeted Proteomics service, with results delivered as clinical testing reports for oncology providers at the point of care.
Product overview
NantOmics offers an integrated panomic molecular diagnostics platform for precision oncology. The core offerings include GPS Cancer (an integrated DNA/RNA/protein analysis platform) and Targeted Proteomics (mass spectrometry-based protein quantification). The company also developed Machine Vision AI Software for digital pathology image analysis. NantOmics was the first company to employ an integrated panomic approach combining whole genome sequencing, RNA sequencing, and quantitative proteomics to inform personalized cancer treatment decisions. The company operates within the NantWorks ecosystem and maintains a cloud-based infrastructure capable of processing thousands of genomes daily.
Differentiator
Problem solved
Functional benefit
Brands
- GPS Cancer: Integrated panomic platform combining whole genome sequencing, RNA sequencing, and quantitative proteomics for personalized cancer treatment decisions
- Targeted Proteomics
Products and services
- GPS Cancer A comprehensive molecular diagnostics platform that integrates whole genome sequencing, RNA sequencing, and quantitative proteomics on a patient's matched tumor and normal samples to provide a complete molecular profile of the cancer, identifying tumor-specific alterations and matching them to targeted therapeutic options for oncology providers at the point of care.
- Targeted Proteomics A quantitative proteomics service using mass spectrometry to measure levels of clinically important proteins from FFPE tumor tissue samples, enabling biomarker analysis and protein expression quantification to support treatment selection for cancer patients.
- Machine Vision AI Software for Digital Pathology Proprietary deep-learning digital pathology software that analyzes whole slide images to identify tumor-infiltrating lymphocytes and classify aggressive breast and lung cancer subtypes, developed jointly with NantHealth to support AI-driven cancer diagnosis.
Quantifiable outcome
- Comprehensive molecular profile from matched tumor and normal samples
- +1 more outcomes
Companies that use NantOmics
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
NantOmics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
NantOmics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- OncoPlex DiagnosticscoreOncoPlex Diagnostics was acquired by NantOmics in September 2015. OncoPlex brought proprietary quantitative proteomic clinical assays, CAP-accredited and CLIA-certified laboratory capabilities, and technical expertise in mass spectrometry analysis for tumor protein profiling. This acquisition expanded NantOmics' molecular diagnostic portfolio.
- NantHealthcoreNantOmics works closely with NantHealth (NASDAQ: NH) on the GPS Cancer platform and Liquid GPS technology. Both companies collaborate on research and development of cancer diagnostics, sharing data presentations at major oncology conferences and co-developing AI-based machine learning digital pathology software for cancer diagnosis.
- NantKwestminorNantKwest (Nasdaq:NK) collaborates with NantOmics on preclinical and clinical data presentations at the American Society of Clinical Oncology Annual Meeting, demonstrating precision medicine tools for cancer treatment analysis.
- NantCellminorNantCell collaborates with NantOmics on data presentations at ASCO Annual Meeting, focusing on advanced deployment of precision medicine tools for cancer analysis.
- NantWorkscoreNantOmics is a member of the NantWorks ecosystem of companies founded by Dr. Patrick Soon-Shiong. The ecosystem includes NantHealth, NantMobileHealth, NantBio, NantCell, NantPharma, NantCapital and NantCloud, operating at the nexus of innovation and infrastructure for personalized healthcare delivery.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
NantOmics competitors and assessment
Company assessmentDirect peers
- Personalis: Genomics and molecular profiling company focused on oncology with focus on whole-genome and RNA sequencing. Directly overlaps with NantOmics' genomic and transcriptomic components of GPS Cancer.
- Caris Life Sciences: Offers molecular profiling (DNA, RNA, protein) and AI-driven analytics for oncology. Highly comparable to NantOmics as both pursue multi-omic tumor profiling and biomarker-driven therapy matching for oncologists.
- Tempus Labs: Multi-modal precision medicine platform combining DNA/RNA sequencing, proteomics, and AI to support oncology decisions. Competes head-to-head with NantOmics' panomic-plus-AI strategy and has a much larger commercial footprint and dataset.
- Guardant Health: Liquid biopsy leader specializing in NGS-based blood-based cancer profiling. Comparable to NantOmics via shared NantHealth Liquid GPS collaboration and adjacent positioning in oncology molecular diagnostics.
- Foundation Medicine: Pioneer in comprehensive genomic profiling of tumors using NGS. Directly comparable to NantOmics' GPS Cancer platform as both provide molecular profiles to oncologists to guide targeted therapy selection, with Foundation Medicine owned by Roche providing scale and distribution advantages.
Broad incumbents
- NeoGenomics: Established oncology-focused clinical laboratory offering a wide menu of molecular and genetic tests. Larger footprint and broader test menu than NantOmics, providing a community-hospital channel alternative to academic precision oncology.
- Exact Sciences: Cancer diagnostics company (including Genomic Health's Oncotype DX) with screening and treatment-selection tests. Comparable as a broad-incumbent oncology diagnostics peer with established payer coverage and global commercial reach.
Emerging players
- Resolution Bioscience: Liquid biopsy and NGS-based oncology diagnostics firm. Compares to NantOmics as a smaller, technology-focused oncology molecular profiling peer (acquired by Agilent in 2021).
- Helio Genomics: Early-stage multi-omics cancer diagnostics company combining genomics, proteomics, and AI. Adjacent emerging peer to NantOmics' panomic approach with overlap in AI-enabled early cancer detection.
- Strata Oncology: Tumor molecular profiling company offering pan-cancer NGS testing for therapy selection. Comparable emerging competitor to NantOmics' GPS Cancer in the same precision oncology niche.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
NantOmics social profiles
Digital presenceNantOmics compliance and trust
Trust signalCompliance2 records
NantOmics financial estimates
Financial estimateRevenue estimate
Valuation estimate
NantOmics leadership team
Management profileNumber of profiles
Profiles3 records
NantOmics subsidiaries and ownership
Company hierarchySubsidiaries1 record
NantOmics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NantOmics M&A and investment
M&A and investmentM&A2 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NantOmics
What does NantOmics do?
NantOmics provides molecular diagnostic testing services that perform whole genome sequencing of matched tumor and normal samples, RNA sequencing, and mass spectrometry-based quantitative proteomics to identify disrupted pathways and match alterations to targeted therapies. The offerings are delivered through CLIA-certified, CAP-accredited laboratories and include the GPS Cancer integrated panomic platform and a Targeted Proteomics service, with results delivered as clinical testing reports for oncology providers at the point of care.
Is NantOmics a public or private company?
NantOmics is a private company. It is classified as corporate owned and is currently operating.
When was NantOmics founded?
NantOmics was founded in 2012. It employs 11 to 50 people.
Where is NantOmics based?
NantOmics is headquartered in Culver City, United States, in the North America region.
How does NantOmics make money?
Two revenue lines are on record. Molecular Diagnostic Testing Services are the primary driver. The others are clinical Testing Reports.
Who are NantOmics's main competitors?
Direct peers on record are Personalis, Caris Life Sciences, Tempus Labs, Guardant Health and Foundation Medicine. Broad incumbents are NeoGenomics and Exact Sciences. Emerging players are Resolution Bioscience, Helio Genomics and Strata Oncology.
Does NantOmics have an API?
No public API is recorded for NantOmics.
What industry is NantOmics in?
NantOmics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAFAMAH, Genetic & Prenatal Testing Laboratories. Its NAICS code is 621511 and its SIC code is 8071.